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Background: The human genome encodes thousands of unique long non-coding RNAs (lncRNAs), and these
transcripts are emerging as critical regulators of gene expression and cell fate. However, the transcriptional
regulation of their expression is not fully understood. The pivotal transcription factor E2F1 which can induce both
proliferation and cell death, is a critical downstream target of the tumor suppressor, RB. The retinoblastoma
pathway is often inactivated in human tumors resulting in deregulated E2F activity.
Results: Here, we report that lncRNA XLOC 006942, which we named ERIC, is regulated by E2F1 and, most
probably, also E2F3. We show that expression levels of ERIC were elevated upon activation of exogenous E2F1, E2F3
or endogenous E2Fs. Moreover, knockdown of either E2F1 or E2F3 reduced ERIC levels and endogenous E2F1 binds
ERIC’s promoter. Expression of ERIC was cell cycle regulated and peaked in G1 in an E2F1-dependent manner.
Inhibition of ERIC expression increased E2F1-mediated apoptosis, suggesting that E2F1 and ERIC constitute a
negative feedback loop that modulates E2F1 activity. Furthermore, ERIC levels were increased following DNA
damage by the chemotherapeutic drug Etoposide, and inhibition of ERIC expression enhanced Etoposide -induced
apoptosis.
Conclusions: Our data identify ERIC as a novel lncRNA that is transcriptionally regulated by E2Fs, and restricts
apoptosis induced by E2F1, as well as by DNA damage.
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Genome-wide transcriptome studies have revealed that the
mammalian genome encodes a novel class of regulatory
genes encoding long non-coding RNAs (lncRNAs), which
are >200 bases in length but lack significant open reading
frames [1]. It is believed that the genome encodes at least
as many lncRNAs as known protein-coding genes [1]. The
expression of many lncRNAs is tissue specific and, in some
cases, restricted to particular developmental contexts [1,2].
Furthermore, thousands of lncRNAs were found to be
evolutionarily conserved [3,4] and exhibit expression
patterns that correlate with various cellular processes
[3-9]. It is now considered likely that this class of ncRNA* Correspondence: doron.ginsberg@biu.ac.il
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reproduction in any medium, provided the orrepresents a significant feature of normal cellular networks.
Specifically, increasing evidence suggests that lncRNAs play
a critical role in regulation of diverse cellular processes such
as stem cell pluripotency, development, cell growth, and
apoptosis [3-9]. Given their abundance and regulatory
potential, it is likely that some lncRNAs are involved in
tumor initiation and progression. In support of this notion,
several lncRNAs are frequently aberrantly expressed in vari-
ous human cancers, with potential roles in both oncogenic
and tumor suppressive pathways [10-14]. Furthermore,
lncRNAs were shown to play active roles in modulating
the cancer epigenome [15].
Recent studies have suggested a number of modes of
action for lncRNAs [16], most notably the regulation of
epigenetic marks and gene expression [6,17-19]. Also,
lncRNAs were shown to function as decoy, scaffold or
guide molecules [1]. Some lncRNAs act in cis to regulateal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lncRNAs can act in trans to repress transcription [22].
Many, although not all, lncRNAs are generated and
processed through mechanisms similar to those that
process mRNA. Specifically, many lncRNAs are transcribed
by RNA polymerase II [23], spliced and polyadenylated
[24]. Additionally, lncRNA promoters are generally bound
and regulated by transcription factors known to influence
mRNA transcription [3,25,26]. One of the p53-regulated
lncRNAs, lncRNA-p21 was shown to play a pivotal role in
the p53-dependent apoptotic response to DNA damage
[22]. Another lncRNA named PANDA was found to play
a critical role in inhibiting p53-mediated apoptosis [5].
E2Fs are transcription factors best known for their in-
volvement in the timely regulation of gene expression
required for cell cycle progression [27]. Members of the
E2F family are downstream effectors of the tumor sup-
pressor, pRB. The critical role of the RB/E2F pathway in
xnormal cellular proliferation is highlighted by the com-
mon incidence among human tumors of pathway muta-
tions that result in deregulated E2F activity [28]. This
deregulated E2F activity results in uncontrolled cell pro-
liferation, a hallmark of tumor cells.
In addition to acting as fundamental regulators of prolifer-
ation, E2Fs modulate diverse cellular functions, such as
DNA repair, differentiation and development [29,30]. At
least one member of the E2F family, namely E2F1, can also
trigger apoptosis [27,31] and autophagy [32-34]. E2F1-
induced apoptosis is mediated by both p53-dependent and
p53-independent pathways [27,35]. In line with the effects of
E2Fs on both proliferation and apoptosis, E2F1 functions
in vivo in a context-dependent manner as an oncogene or a
tumor suppressor [36]. Currently, little is known about tran-
scriptional regulation of lncRNAs by E2F1 or the role played
by lncRNAs in E2F1-regulated biological functions.
In the present study, we characterized XLOC 006942,
a novel lncRNA that we named ERIC (E2F1-Regulated
Inhibitor of Cell death). We demonstrate here that ERIC
is transcriptionally up-regulated by E2F1 as well as by
DNA damage, and we show that inhibition of ERIC aug-
ments apoptotic cell death induced by either E2F1 or a
DNA damaging agent.
Results
E2F directly regulates expression of ERIC in a
p53-independent manner
To explore if E2F1 regulates expression of long non-
coding RNAs (lncRNAs) we took advantage of a human
osteosarcoma cell line U2OS and a human lung carcin-
oma cell line H1299 that each express conditionally ac-
tive E2F1, namely ER-E2F1 [37]. We reasoned that E2F1
activation might result in increased expression of not
only protein coding genes but also lncRNAs. We acti-
vated E2F1 for either 8 or 16 hours and surveyed RNAtranscript levels in the U2OS and H1299 cells using RNA
Seq analysis. In accord with published data, many known
E2F1-regulated protein-coding genes exhibited increased
expression upon E2F1 activation (Figure 1A and data not
shown). The E2F1-induced upregulation of these genes
validated our experimental system and served as an in-
ternal positive control. Notably, in line with our hypoth-
esis, we detected increased expression of many lncRNAs
upon activation of E2F1. Our analysis of the RNA Seq data
was based on the recently published genomic coordinates
of 8,196 long intergenic non-coding RNAs (lincRNAs)
[38]. Out of these 8,196 lincRNAs, 5,998 lincRNAs were
not expressed in either of the two cell lines we analyzed.
When studying the remaining 2,198 lincRNAs that were
expressed in at least one cell line we found that expression
of 137 lincRNAs was upregulated more than two fold at
both time points in at least one of the cell lines after activa-
tion of E2F1 (Additional file 1: Table S1). From this group
of lincRNAs putatively regulated by E2F1, we chose to focus
on lincRNA XLOC 006942, which we named ERIC (E2F1-
Regulated Inhibitor of Cell death); this lncRNA exhibited in-
creased RNA levels upon activation of E2F1 in both cell
lines (Figure 1A). ERIC (also termed TCONS_00014875) is
located on chromosome 8 (chr8:141646242-141648531) at a
position corresponding to band 8q24.3 on a somatic map,
and is transcribed from the plus strand. ERIC is composed
of two exons and its transcript size is 1745 bp.
To validate and extend the RNA-Seq data, we per-
formed real-time PCR analysis of ERIC levels in four cell
lines, each expressing the conditionally active E2F1, ER-
E2F1. As can be seen in Figure 1B, activation of the ec-
topic E2F1 by addition of its inducer, 4-hydroxytamoxifen
(OHT), resulted in a significant increase in ERIC RNA
levels in the U2OS and H1299 lines described above, as
well as another human osteosarcoma cell line, SAOS-2,
and WI38 human embryonic lung fibroblasts. As ex-
pected, addition of OHT to U2OS cells lacking the indu-
cible E2F1 (“Vec”) did not affect ERIC mRNA levels,
validating the role of E2F1 in the upregulation (Figure 1B).
Similarly, transient transfection of wt E2F1, but not of a
mutant E2F1 that does not bind DNA (E2F1E132), into
U2OS cells also resulted in a significant increase in
ERIC RNA levels (Figure 1C). Notably, activation of
conditional E2F3 also resulted in significantly increased
ERIC RNA levels (Additional file 2: Figure S1A). Taken
together, these data suggest that an activity common to
E2F1 and E2F3 is responsible for up-regulating ERIC
expression.
In addition to directly activating gene expression, E2F1
can also activate p53 [39]; therefore activation of a gene
by E2F1 may represent indirect activation via p53. How-
ever, the observed E2F1-mediated upregulation of ERIC
was p53-independent since it is also observed in H1299
cells and SAOS-2 cells, both of which lack wt p53.
Figure 1 Ectopic E2F1 expression directly upregulates ERIC RNA levels. A) U2OS and H1299 cells containing conditionally active E2F1 were
induced to activate E2F1 by OHT (times indicated). RNA was extracted and RNA deep-sequencing analysis was employed. FI- fold of increase in RNA levels
after E2F1 induction, determined by RNA sequencing. B) U2OS, H1299, WI38 and SAOS-2 cells containing conditionally active E2F1 were induced to
activate E2F1 by addition of OHT (times indicated). RNA was extracted, and ERIC RNA levels determined by Real- time RT-PCR and normalized to GAPDH.
U2OS cells containing an empty vector (vec) served as a control. C) U2OS cells were transfected with an empty vector (Vec) or a vector expressing either
wild type E2F1 (E2F1) or mutant E2F1 (E2F1 mut). Upper panel- RNA was extracted and ERIC RNA levels determined by Real-time RT-PCR and normalized
to GAPDH. Lower panel- Proteins were extracted and western-blot analysis performed using antibodies directed against E2F1 and GAPDH. D) Induction of
ERIC by E2F1 is p53-independent. U2OS cells stably expressing ER- E2F1 were infected with either a retrovirus expressing non specific shRNA (shNS) or a
retrovirus expressing shRNA directed against p53 (shp53). Cells were left untreated (-) or incubated with OHT (100nM) for 16 hr (+). Upper panel- RNA was
extracted and ERIC RNA levels were determined by real-time RT-PCR and normalized to GAPDH. Lower panel- Proteins were extracted and western-blot
analysis was performed using antibodies directed against p53 and Actin. E) Induction of ERIC does not require protein synthesis. U2OS cells expressing
ER-E2F1 were left untreated or incubated with OHT (100 nM, 8 hr); cells were then treated or not with 10 μg/mL cycloheximide (CHX) for 8 h. RNA was
extracted and ERIC RNA levels determined by real-time RT-PCR and normalized to GAPDH. The average of two independent experiments is presented.
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induced ERIC expression levels in the p53 proficient
U2OS cell line even in the presence of shRNA directed
against p53 (Figure 1D). To further examine whether E2F
regulates ERIC directly or indirectly, ectopic E2F1 was acti-
vated in the presence of the inhibitor of protein synthesis,
cycloheximide. In support of direct regulation, E2F1 activa-
tion in the presence of cycloheximide did not mitigate
ERIC RNA induction (Figure 1E).Endogenous E2F regulates ERIC expression
To further support the notion that endogenous E2Fs are
capable of regulating ERIC expression, we took advan-
tage of the Human Papilloma Virus oncoprotein E7,
which disrupts RB/E2F complexes, resulting in activa-
tion of endogenous E2Fs. In line with our results using
inducible E2F, expression of E7 in WI38 human fibro-
blasts elevated the levels of ERIC, when compared to a
mutant E7, E7Δ21-35, which does not disrupt RB/E2F
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ment of endogenous E2F1 in controlling ERIC expres-
sion, the effect of E2F1 knockdown on ERIC RNA levels
was studied. To this end, two distinct siRNAs directed
against E2F1 were introduced to U2OS cells; as ex-
pected, siRNA inhibition resulted in reduction of E2F1
protein levels (Figure 2B, lower panel). When the effect
of knockdown on ERIC was tested, E2F1 knockdown re-
sulted in significantly reduced endogenous ERIC RNA
levels (Figure 2B). Similar results were obtained upon si-
lencing of E2F1 in SAOS-2 cells (Additional file 3:
Figure S2). Additionally, E2F3 knockdown in U2OS cells,
by two distinct siRNAs, resulted in reduced endogenousFigure 2 Endogenous E2F1 regulates expression of ERIC. A) WI38 cells
RB-binding–deficient E7 mutant (E7-mut). Upper panel-RNA was extracted and
GAPDH levels. Lower panel- proteins were extracted and western blot analysis
B) Upper panel- U2OS cells were transfected with either a nonspecific siRNA (
and ERIC RNA levels determined by Real-time RT-PCR and normalized to GAPD
blot analysis performed using antibodies directed against E2F1 and actin. C) U
E2F-binding site is represented as 8-mer nucleotide sequences. The transcripti
RT-PCR is represented by arrows (−523/−10). Lower panel- Chromatin Immuno
chromatin was precipitated using antibodies specific to E2F1 or IgG. Then, ERI
represents 0.5% of total chromatin.ERIC RNA levels (Additional file 2: Figure S1B, C). Also,
analysis of the human genomic sequence upstream to ERIC
identified a putative E2F binding site at –221/-214 (TSS
according to [38]) suggesting that endogenous E2Fs
indeed bind upstream to ERIC. Further support for this
notion was sought using Chromatin Immunoprecipitation
analysis (ChIP). Chromatin was isolated from proliferating
U2OS cells and incubated with an antibody directed
against E2F1 and as predicted, endogenous E2F1 was
detectably associated with the human genomic sequence
upstream to ERIC (Figure 2C). Taken together, these data
demonstrate that both endogenous and ectopically
expressed E2F1 and E2F3 regulate ERIC levels.were infected with a retrovirus expressing either wild-type E7 (E7) or an
ERIC RNA levels determined by Real-time RT-PCR and normalized to
performed using antibodies directed against E2F1, CCNE1 and Actin.
siNS) or an siRNA directed against E2F1 (si#1 and si#2). RNA was extracted
H levels. Lower panel- Proteins were extracted from cells and western
pper panel- a schematic representation of the human ERIC promoter. The
on start site (+1) is indicated by an arrow. The DNA fragment amplified by
Precipitation analysis was conducted using U2OS cells. Cross-linked
C and Actin promoter fragments were amplified by RT-PCR. Input DNA
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regulated, we examined its RNA levels in WI38 cells that
were growth arrested at G1 by serum starvation and
induced to reenter the cell cycle by addition of 15% FBS.
Under these conditions, we detected a rapid and transient
increase in ERIC RNA levels as arrested cells resumed
growth (Figure 3A). Specifically, ERIC levels increased 11
and 6 fold, 4 and 8 hours after serum addition, respectively.
This transient increase in ERIC levels slightly preceded
G1/S transition of the serum-stimulated cells (Figure 3B).
Of note, knock down of E2F1 significantly inhibits ex-
pression of ERIC both in starved cells and upon release
from starvation (Figure 3C). Thus, our data suggest that
endogenous E2F1 regulates ERIC expression both in cycling
cells and in arrested cells that resume growth.
ERIC inhibits E2F1-induced apoptosis
To directly determine whether ERIC plays a role in E2F1-
induced biological processes, we reduced endogenous ERICFigure 3 ERIC is cell cycle regulated. WI38 cells were growth arrested by se
then allowed to resume growth by serum addition (to a final concentration of 15
were determined by Real-time RT-PCR and normalized to GAPDH levels. B) Cell cy
G1, S and G2/M are indicated. C)WI38 cells were transfected with either a nonspe
growth arrested by serum deprivation (48 hours in medium with 0.1% serum, S =
concentration of 15%) for the times indicated. Left panel-RNA was extracted and
GAPDH levels. Right panel-Proteins were extracted from the cells, and western bloRNA levels in U2OS cells by two distinct siRNA, and
examined the effect(s) on E2F1-induced G1/S transition
as well as E2F1-induced apoptosis. Introduction of each
of these two siRNAs resulted in significantly reduced
basal levels of ERIC RNA and inhibited its up regulation
by E2F1 compared to non-specific siRNA (Figure 4A).
Having established the efficacy of the ERIC-specific
siRNAs, we examined the effects of ERIC knockdown on
E2F1-mediated biological processes. In line with previous
reports, activation of ectopic E2F1 resulted in S phase
entry as well as apoptosis. Apoptosis was evaluated by
monitoring the percentage of cells with sub-G1 DNA
content and also by monitoring the levels of cleaved
caspase 3 (Figure 4B, C, D). Despite the increase of ERIC
RNA levels as arrested cells resume growth (Figure 3), ab-
lation of ERIC did not have a significant or reproducible
effect on the E2F1-induced G1/S transition (Figure 4B).
Similarly, ablation of ERIC did not have a significant effect
on cell viability and cell cycle distribution (Figure 4B, leftrum deprivation (48 hours in medium with 0.1% serum, S = starvation) and
%) for the times indicated. A) RNA was extracted and RNA levels of ERIC
cle distribution was determined using FACS analysis. Percentage of cells in
cific siRNA (siNS) or an siRNA directed against E2F1 (siE2F1). Then cells were
starvation) and then allowed to resume growth by serum addition (to a final
RNA levels of ERIC were determined by Real-time RT-PCR and normalized to
t analysis performed using antibodies directed against E2F1 and actin.
Figure 4 ERIC restricts E2F1-mediated apoptosis. U2OS cells stably expressing ER-wild type E2F1 were transfected with either a nonspecific
siRNA (siNS) or an siRNA directed against ERIC (si#1 or si#2). Then, cells were left untreated or incubated with OHT (100 nM) for times indicated.
A) RNA was extracted and ERIC RNA levels were determined by real-time RT-PCR and normalized to GAPDH levels. One representative
experiment is shown out of 3 repeats. B) Cells were analyzed by fluorescence-activated cell sorting (FACS) analysis using propidium-iodide (PI)
staining. One representative experiment is shown. Numbers represent percent of cells with a subG1 DNA content. C) Summary of three
independent FACS experiments. D) Proteins were extracted from the cells, and western blot analysis performed using antibodies directed against
cleaved caspase 3 and actin.
Feldstein et al. Molecular Cancer 2013, 12:131 Page 6 of 12
http://www.molecular-cancer.com/content/12/1/131histograms). Interestingly, the knockdown of ERIC signifi-
cantly enhanced E2F1-induced apoptosis as evident by the
reproducible increase in the percentage of cells with sub
G1 DNA content as well as the increase in cleaved caspase
3 (Figure 4B, C, D). This effect of ERIC ablation on E2F1-
induced apoptosis was also evident in similar experiments
performed using H1299 cells (Additional file 4: Figure S3)
and SAOS-2 cells (data not shown). Taken together, these
data suggest a negative feedback loop in which the E2F1-
regulated ERIC inhibits E2F1-induced apoptosis.
ERIC is upregulated upon DNA damage and inhibits DNA
damage-induced apoptosis
Having demonstrated a possible inhibitory role for ERIC
in E2F1-mediated apoptosis, we next investigated the
function of ERIC in a chemotherapeutic agent-induced
apoptosis of transformed cells. Administration of the che-
motherapeutic drug etoposide to U2OS cells resulted in
apoptotic cell death (Figure 5A inner panel) and aconcomitant increase in ERIC RNA levels (Figure 5A).
This damage-induced increase in ERIC RNA levels is most
probably E2F1-independent since we detect a decrease in
E2F1 protein levels after damage (Figure 5B lower panel),
nevertheless it represents an upregulation of ERIC in re-
sponse to a physiological stimulus. Silencing of ERIC,
using two distinct siRNAs (Figure 5B), did not affect cell
viability (Figure 5C left histograms) but when combined
with etoposide it resulted in a significant augmentation of
etoposide-induced apoptosis (Figure 5C, right histograms).
These results were also evident in H1299 cells (Additional
file 5: Figure S4). These results suggest that ERIC inhibits
etoposide-induced apoptosis, thereby modulating the
cellular response to chemotherapy.
Discussion
As a master regulator for gene expression, E2F1 is able to
directly or indirectly regulate numerous protein-coding and
non-coding genes, especially microRNAs. For example,
Figure 5 DNA damage upregulates ERIC RNA levels, and ERIC restricts DNA damage-induced apoptosis. A) U2OS cells were treated with
etoposide (50 μg/ml) for times indicated. RNA was extracted from cells and ERIC RNA levels were determined by real-time RT-PCR and
normalized to GAPDH. One representative experiment out of 4 is shown. Inner bar-graph indicates percent of cells exhibiting subG1 DNA content
at each time point, as analyzed by FACS.
U2OS cells were transfected with either a nonspecific siRNA (NS) or an siRNA directed against ERIC (si#1 or si#2). Then, cells were left untreated or
incubated with etoposide (Etop) (50 μg/ml) for 24 hours. B) Upper panel- RNA was extracted and ERIC RNA levels were determined by real-time RT-
PCR and normalized to GAPDH levels. Lower panel- Proteins were extracted from cells and western blot analysis performed using antibodies directed
against E2F1 and GAPDH. C) Cells were analyzed by FACS following propidium-iodide (PI) staining. One representative experiment out of 3 is shown.
Numbers represent percent of cells with a subG1 DNA content. D) Summarized results of three independent FACS experiments, *P value = 0.01
(Two-tailed Student’s T-test).
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are induced by E2F [40,41]. Similarly, we have shown that
expression of miR-15 and miR-16 is up-regulated by E2F1
[42]. The present study suggests that lncRNAs can also be
subject to E2F1 regulation. Aberrant expression of lncRNAs
is often associated with human diseases, in particular
cancer [43].
In this study, we demonstrated that ERIC expression is
regulated by E2Fs. Specifically, we show that activation
of ectopic E2F1 or E2F3 result in elevated levels of ERIC
RNA. The effect of E2F1 is direct and p53-independent.
Moreover, we demonstrate that expression of this lncRNAis induced by E7, a viral protein that derepresses endogen-
ous E2Fs. Furthermore, we show that ERIC expression is
reduced in response to knock down of endogenous E2F1
or endogenous E2F3 and endogenous E2F1 binds ERIC’s
promoter. Having established E2F regulation of ERIC, we
also provide evidence that its RNA levels are elevated, in
an E2f1-dependent manner, during resumption of growth
following cell cycle arrest (Figure 3). Also, ERIC RNA
levels are elevated in response to DNA damage (Figure 5A)
[27]. Recent studies have identified lncRNAs whose
expression is affected by cell cycle progression [3] or geno-
toxic stress [44]; however, regulation of their expression
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depth.
The expression of the lncRNAs H19 and ANRIL was
shown to be regulated by E2F1 [45,46] and, to our
knowledge, ERIC is the third lncRNA reported to be
subject to E2F-regulation. Our RNA-Seq data suggest
that more than a hundred lincRNAs are reproducibly
regulated by E2F1; therefore, H19, ANRIL and ERIC
most probably represent just the tip of the iceberg with
regard to the full repertoire of E2F-regulated lncRNAs.
Validating the regulation of additional lncRNAs by E2F
as well as elucidating the role(s) such lncRNAs play in
E2F1-mediated biological functions awaits future research.
Clearly, further characterization of those potential lncRNAs
will increase our understanding of how lncRNAs are
integrated into the E2F-regulatory network.
The biological function(s) of lncRNAs are only now
beginning to be elucidated; we show here that inhibition
of ERIC expression augments E2F1-induced as well as
etoposide-induced apoptosis (Figure 4, 5), suggesting that
ERIC has an inhibitory effect on apoptosis in these settings.
The mode of action of ERIC remains to be determined.
Most lncRNAs are nuclear [47] and many of them function
in the regulation of gene expression. Our data, indicating
that ERIC is largely nuclear (not shown), are in agreement
with such a mechanism. Moreover, our DNA microarray
data show that upon combined treatment of E2F1 activa-
tion and ERIC silencing in U2OS cells the expression of
some E2F1-regulated apoptosis-related genes is significantly
altered in a manner that is in agreement with enhancement
of E2F1-induced apoptosis by ERIC silencing. However, the
detailed effect of ERIC on gene expression awaits further
studies.
With respect to the inhibitory effect of ERIC on E2F1-
induced apoptosis, our data suggest the existence of a
negative feedback loop: E2F1 activates expression of the
lncRNA ERIC, which in turn, restricts the apoptotic
function of E2F1.
This is not the first example of such a negative feedback
loop regulating E2F activity, and in fact the RB/E2F path-
way encompasses many such negative feedback loops. For
example, we showed previously that E2F1 activates AKT
via transcriptional regulation of the adaptor Gab2, and
that this E2F1-dependent AKT activation serves to inhibit
E2F1-mediated apoptosis [48]. Also, E2F1 and E2F3
were shown to transcriptionally up-regulate the expression
of a number of miRNAs that can, in turn, inhibit cell pro-
liferation [42,49].
We show here that ERIC is transcriptionally regulated by
E2F1 and can mitigate E2F1 apoptotic activity. We propose
that this lncRNA might fine-tune E2F1 activity, thereby
preventing excessive E2F1 activity, which could harm nor-
mal cells. For example, its increase as arrested cells resume
growth (Figure 3) may be one of the molecular mechanismsinhibiting E2F1-induced apoptosis at the G1/S transition.
Of course, other mechanisms have been suggested to in-
hibit E2F1-induced apoptosis at the G1/S transition, for ex-
ample regulation via the Akt pathway [50]. ERIC may be
another layer in a multilayer regulatory pathway that pre-
vents E2F1-induced apoptosis from occurring at the
“wrong” time.
With respect to the inhibitory effect of ERIC on
etoposide-induced apoptosis, our data demonstrate that
ERIC RNA levels increase in response to DNA damage,
and inhibition of ERIC expression augments damage-
induced apoptosis. Thus, the anti-apoptotic function of
ERIC is not limited to the artificial setting of ectopic E2F1
activation, as we showed it to play a role also in a more
physiological setting, the cellular response to DNA damage
by a chemotherapeutic agent. ERIC may have cancer-
promoting effects, as well as conferring chemo-resistance,
as it supports survival in the face of DNA damage. Thus,
our data suggest that in the future, the level of ERIC RNA
may serve as one of the parameters to predict patient
response to DNA damaging chemotherapeutic drugs.
Clearly, additional work is required to establish the pre-
dictive power of ERIC levels.
We and others have previously shown that ectopic ex-
pression of E2F1 synergizes with chemotherapeutic drugs
in inducing apoptosis [51-53], however other studies
showed that under some conditions, elevated E2F1 activity
can lead to chemo-resistance [54]. The E2f1-induced up-
regulation of ERIC may represent one of several molecular
mechanisms underlying such E2F1-mediated modulation
of the response to chemotherapeutic drugs.
Conclusions
This study reveals a novel regulatory loop, consisting of
the transcription factor, E2F1, and a novel E2F1-
regulated lncRNA XLOC 006942, which we have named
ERIC. This loop is shown here to influence cell viability
and thus, to control cell fate. Furthermore, our findings
demonstrate that ERIC modulates the cellular response to
chemotherapy. Given the key role of the E2F network in
cancer biology, better understanding of the crosstalk be-
tween the players, such as between ERIC and E2F, should
ultimately advance our understanding of cancer biology,
and our ability to develop effective therapies.
Materials and methods
Cell culture
U2OS and SAOS-2 osteosarcoma cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with 5%
fetal calf serum (FCS). Early passage WI38 human embry-
onic lung fibroblasts were grown in minimal essential
medium supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 1 mM sodium pyruvate and non-essential
amino acids. H1299 human lung adenocarcinoma cells were
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calf serum. Cells were maintained at 37°C in a humidified at-
mosphere containing 8% CO2. To induce activation of ER-
E2F1, cells were treated with 100 nM 4-hydroxytamoxifen
(OHT, Sigma) for the times indicated. Where indicated, cy-
cloheximide (Sigma) was administered for 8 hr at 10 μg/ml.
Etoposide (Sigma) was used at 50 μg/ml.Quantitative PCR (Real-Time RT- PCR)
Total RNA was extracted from the cells using the Tri
Reagent method. Real-time quantitative PCR (qPCR)
was done using SYBR Green PCR Master Mix (Applied








All real-time reverse transcriptase PCR (RT-PCR)
reactions were performed using the Applied Biosystems
StepOnePlus Real-Time PCR Systems Machine. Results
are presented as mean and SD for duplicate runs.Western blotting
Cells were lysed in lysis buffer [50 mmol/L Tris (Ph 7.5),
150 mmol/L NaCl, 1 mmol/L EDTA, 1% NP40] in the pres-
ence of protease inhibitor cocktail (Roche) and phosphatase
inhibitor cocktails I and II (Sigma). Equal amounts of pro-
tein, as determined by the Bradford assay, were resolved by
electrophoresis in a SDS 10% or 12.5% polyacrylamide gel
and then transferred to a PVDF membrane (Millipore). The
membrane was incubated with one of the following pri-
mary antibodies: anti-cleaved caspase-3 (Cell Signaling);
anti-E2F1 (sc-251, Santa Cruz Biotechnology); anti-
CCNE1 (sc-247, Santa Cruz Biotechnology); anti-E2F3
(sc-878, Santa Cruz Biotechnology); anti-actin (sc-1616r,
Santa Cruz Biotechnology); anti-tubulin (T9026, Sigma);
anti-GAPDH (sc-25778, Santa Cruz Biotechnology) or
anti-P53 (sc-126, Santa Cruz Biotechnology). Binding of
the primary antibody was detected using an enhanced
chemiluminescence kit (ECL Amersham).Plasmids
The plasmids pBabe-neo-HA-ER-E2F1, pBabe-puro-HA,
pBABE-puro-16E7 and pBABE-puro-E7-dl21-35 [55],
pCDNA3.1(+), pCDNA3-E2F1, pCDNA3.1-HA-E2F1-
E132 and pRETROSUPER-shp53.Transfection/infection procedures
To generate retroviruses, cells (2 × 106) of the packaging
cell line 293 T were cotransfected with ecotropic pack-
aging plasmid pSV-EMLV (10 μg), which provides pack-
aging helper function, and the relevant plasmid (10 μg)
using the calcium phosphate method in the presence of
chloroquine (Sigma). After 8 hr, the transfection
medium was replaced with fresh Dulbecco’s modified
Eagle’s medium supplemented with 5% fetal calf serum.
Subsequently, cell supernatants containing retroviruses
were collected.
For infection, cells were incubated for 5 hr at 37°C in
4.5 mL of retroviral supernatant supplemented with
polybrene (8 μg/mL, Sigma H9268). Then, 5.5 mL of
medium was added and after a further 24 hr, the
medium was replaced with fresh medium containing
puromycin (2 μg/mL, Sigma P7130).
When transfecting U20S, SAOS-2 or H1299 cells with
siRNA, Interferin transfection reagent (PolyPlus-transfec-
tion) was employed according to the manufacturer’s in-
structions. The siRNAs against ERIC (si#1: AAGCCAGCC
TGTGGCTACCTCCTTT, si#2: CCCGTGGCATCGGCT
GTCTGCATAT), SiE2F1(si#1- CUGAGGAGUUCAUCAG
CCU si#2- CAGAGCAGAUGGUUAUGGU), siE2F3 (si#1-
GCCUUAAAGACCAAACUGU, si#2- CAUAUCAAGAU
AUUCGAAA) and a control sequence (siRNA universal
negative control #1), were synthesized by Sigma-Aldrich.
Experiments were performed 48 hours after transfection
with siRNAs. When transfecting U20S cells with plasmids,
polyjet transfection reagent (Signagen) was employed
according to the manufacturer’s instructions.
Chromatin immunoprecipitation
DNA–protein complexes were immunoprecipitated from
U2OS cells using the ChIP (chromatin immunoprecipita-
tion) assay kit (Upstate Biotechnology) according to the
manufacturer’s protocol with the following antibodies: anti-
E2F1 (sc-193; Santa Cruz Biotechnology) and anti IgG
(111-035-144, Jackson Immunoresearch). Anti-IgG served
as a control for nonspecific DNA binding. The precipitated
DNA was subjected to RT- PCR analysis using specific
primers corresponding to the human ERIC promoter (5′-
GCCTCGCCAAACAGGTTTAC and 5′- ACTACAGAAA
CACGGAGGTCG) as well as primers for β-Actin that
served as a negative control (5′- ACGCCAAAACTCTCC
CTCCTCCTC and 5′- CATAAAAGGCAACTTTCGGAA
CGGC).
Fluorescence-activated cell sorting analysis
Cells were trypsinized and then fixed by incubating in 70%
ethanol at 4°C overnight. After fixation, cells were centri-
fuged for 4 min at 1500 rpm, and the pellet resuspended
and incubated for 30 min at 4°C in 1 ml of PBS. Then,
the cells were centrifuged again and resuspended in PBS
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RNase A. After incubation for 20 min at room temperature,
fluorescence intensity was analyzed using a Becton Dick-
inson flow cytometer.
RNA Seq analysis
Six RNA samples (three from U2OS and three from
H1299) were analyzed by Illumina Genome Analyzer
IIx. Ribosomal RNA was removed from total RNA samples
(using Ribo-Minus kit) to enrich mRNA concentration.
Random primers were used to produce cDNA. Each RNA
sample contained approximately 30 million reads with a
read length of 36 nucleotides. The reads were aligned to
the human genome (hg19) using bowtie (v0.12.8) [56] and
TopHat (v1.2.0) [57]. For each sample, approximately 10
million reads were successfully aligned to the genome.
Read counts per gene were calculated for each sample
with htseqcount (http://www-huber.embl.de/users/an-
ders/HTSeq). DESeq (v1.2.1) [58] was used to identify
genes that were differentially expressed across the
conditions.
Additional files
Additional file 1: Table S1. LincRNAs that are expressed in at least
one of the studied cell lines. Data collected from RNA sequencing
analysis that was performed using U2OS and H1299 cells containing an
ER-E2F1 expression vector. Table contains number of reads and fold
induction results of lincRNAs levels after OHT treatment for 8 and 16
hours. Marked in yellow- 137 lincRNAs that were upregulated more than
two fold at both time points in at least one of the cell lines after
activation of E2F1. Inf (infinity)-represents a positive number divided by
zero meaning, lincRNA is not expressed in basal state (before E2F1
induction). NA (not available) - represents division of zero by zero
meaning, lincRNA is not expressed both before and after E2F1
activation.
Additional file 2: Figure S1. E2F3 expression regulates ERIC RNA
levels. A) U2OS cells containing conditionally active E2F3 were
induced to activate E2F3 by addition of 4- hydroxyTamoxifen (OHT)
for the times indicated. ERIC RNA levels were determined by Real-
time RT-PCR and normalized to GAPDH. B) Upper panel- U2OS cells
were transfected with either a nonspecific siRNA (siNS) or an siRNA
directed against E2F3 (si#1 and si#2). RNA was extracted from the
cells and E2F3 RNA levels determined by Real-time RT-PCR and
normalized to GAPDH levels. Lower panel- Proteins were extracted
from cells and western blot analysis performed using antibodies
directed against E2F3 and GAPDH. C). RNA extracted from cells
described in B and ERIC RNA levels determined by Real-time RT-PCR
and normalized to GAPDH levels.
Additional file 3: Figure S2. Endogenous E2F1 regulates expression of
ERIC in SAOS-2 cells. SAOS-2 cells were transfected with either a
nonspecific siRNA (siNS) or an siRNA directed against E2F1 (siE2F1). Upper
panel- RNA was extracted and ERIC RNA levels determined by Real-time
RT-PCR and normalized to GAPDH levels. Lower panel- Proteins were
extracted from cells and western blot analysis performed using
antibodies directed against E2F1 and GAPDH. Orit-replace with a single si
figure + change legend accordingly.
Additional file 4: Figure S3. ERIC restricts E2F1-mediated apoptosis in
H1299 cells. H1299 cells stably expressing ER-wild type E2F1 were
transfected with either a nonspecific siRNA (siNS) or an siRNA directed
against ERIC (si#1 or si#2). Cells were then left untreated or incubated
with OHT (100 nM) for 20 hours. A) RNA was extracted, and ERIC RNAlevels were determined by real-time RT-PCR and normalized to GAPDH
levels. One representative experiment is shown. B) Proteins were
extracted from the cells, and western blot analysis was performed using
antibodies directed against cleaved caspase 3 and tubulin.
Additional file 5: Figure S4. ERIC restricts DNA damage induced
apoptosis in H1299 cells. A) H1299 cells were transfected with either a
nonspecific siRNA (NS) or an siRNA directed against ERIC (si#1 or si#2).
Then, cells were left untreated or incubated with etoposide (Etop)
(150 μgr/ml) for 20 hours. Upper panel- RNA was extracted and ERIC RNA
levels were determined by real-time RT-PCR and normalized to GAPDH
levels. One representative experiment is shown. Lower panel- Proteins
were extracted from the cells, and western blot analysis performed using
antibodies directed against cleaved caspase 3 and actin. B) Cells were
analyzed by FACS using propidium-iodide (PI) staining. One
representative experiment is shown. Numbers represent percent of cells
with a subG1 DNA content.
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